PharmiWeb

Faron Announces Two Bexmarilimab Abstracts Accepted At Ash 2025, Including An Oral Presentation On Treatment Efficacy

This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to ...
PharmiWeb

BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts ...

VANCOUVER, BC / ACCESS Newswire / November 4, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, ...
PharmiWeb

Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding

Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation TechnologyExpert consensus predicts integration of CTC testing into ...
PharmiWeb

Empowering Growth: Needle-Free Injection System Market

The Needle-Free Injection System Market represents a groundbreaking advancement in medical technology, offering an innovative ...
PharmiWeb

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the ...
PharmiWeb

FluoGuide A/S Intends to Carry Out a Directed Share Issue of Approximately SEK 100 Million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER ...
PharmiWeb

FluoGuide A/S Issue Warrants to Board Members, Executive Management and Employees

COPENHAGEN, DENMARK / ACCESS Newswire / November 3, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, ...
PharmiWeb

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
PharmiWeb

Medical Care Technologies, Inc (OTC PINK:MDCE) Announces Development of AI-Powered Wellness App Suite with Global Reach

Generation Wellness to a Global Audience with Multilingual, Accessible AI Solutions MESA, ARIZONA / ACCESS Newswire / November 3, 2025 / Medical Care Technologies, Inc. (OTC Pink:MDCE) is excited to ...
PharmiWeb

Voters and researchers head to Parliament to see how politicians are using evidence

Voters and researchers head to Parliament to see how politicians are using evidenceThe public has made it clear that they expect MPs to look at the evidence when making decisions[1]. Following a ...
PharmiWeb

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / ...
PharmiWeb

BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first ...